Glenmark Sets Bold FY27 Growth & Margin Targets

Key Highlights Revenue Growth: Aims for 13–15% CAGR over the next 2 years. EBITDA Margin: On track to reach 23% by FY27. Return Ratios: Targeting ROCE >23% and ROE >20%, while maintaining a net cash position. Innovation: Plans one IND filing annually. Capex/Investment: Average yearly investment of ~$70 million. 📊 Fundamentals Snapshot Metric Target FY27 Implication Revenue CAGR 13–15% Consistent growth trajectory. EBITDA Margin 23% Margin expansion from efficiency & product mix. ROCE >23% Strong capital efficiency. ROE >20% High shareholder return potential. Net Cash Maintain Conservative balance sheet. IND Filings 1 annually Pipeline expansion. ⚡ Growth Drivers Expansion in specialty & branded generics. Focus on R&D and IND filings. Margin expansion via cost optimization & product mix. Strong presence in US, EU, and emerging markets. ⚠️ Risks Regulatory challenges in US/EU. Currency volatility impacting exports. Competition from peers in generics and specialty pharma.